And the 2022 data is attached.

Notes on this data:

A few notes about the data:

* We used panel sample along with client sample provided by NCCS, the sponsor of the study, but most of reporting was on the panel sample..  To select just panel sample, exclude Quota\_Sample=2 – the total n size =1408 for the panel sample, n=670 for client sample.
  + **Nationwide Survey of Adult Cancer Patients and Survivors**
  + Nationwide sample of n=1408, fielded July 12th – August 8th, 2022, Quota\_Sample not =2
  + Oversamples of Stage IV/Metastatic Breast cancer patients to analyze this group with more statistical reliability
  + Set quotas to make sure the sample was representative by age, gender, race/ethnicity, and region (using ACS and NCI data) and weighted the data to targets
  + Oversamples of Stage IV/Metastatic patients to analyze this group with more statistical reliability
  + Surveys were recruited through an online non-probability sample with quotas set to ensure demographically representative audiences, following AAPOR best practices

* + **Nationwide Survey of “NCCS Connected” Patients and Survivors**
  + Nationwide sample of n=670, same field period as above, Quota\_Sample=2
  + Emailed invitation to all NCCS email contacts, inviting them to take the survey + 2 reminders